Autoimmune lymphoproliferative syndrome medical therapy
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome medical therapy |
|
FDA on Autoimmune lymphoproliferative syndrome medical therapy |
|
CDC on Autoimmune lymphoproliferative syndrome medical therapy |
|
Autoimmune lymphoproliferative syndrome medical therapy in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome medical therapy |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome medical therapy |
Editor-In-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] David Teachey, MD [2] Associate Editor(s)-in-Chief: Sharmi Biswas, M.B.B.S
Overview
Currently, there is no standard curable treatment for Autoimmune lymphoproliferative syndrome ALPS. Treatment of different features of ALPS as cytopenias, autoimmune syndromes as well as monitoring and treating the consequences as splenomegaly, lymphoma can be helpful.
Treatment
- Mostly commonly directed at autoimmune disease
- Maybe needed to treat bulky lymphoproliferation
- First line therapies
- Corticosteroids
- Very active but toxic with chronic use
- IVIgG
- Not as effective as in other immune cytopenia syndromes
- Corticosteroids
- Second line therapies
- Mycophenolate mofetil (cellcept)[1]
- Inactivates inosine monophosphate
- Active in most patients
- Most studied medicine in clinical trials
- Some patients have complete resolution of autoimmune disease
- Some patients have partial responses
- Some patients relapse
- Does not affect lymphoproliferation or reduce DNTs
- Well-tolerated: Side effects: Diarrhea, neutropenia
- Does not require therapeutic drug monitoring
- No drug-drug interactions
- Can cause hypogammaglobulinemia (transient) requiring IVIgG replacement
- Consider PCP prophylaxis but usually not needed
- Sirolimus (rapamycin, rapamune)
- mTOR (mammalian target of rapamycin) inhibitor[2]
- Active in most patients
- Second most studied agent in clinical trials
- Most patients have complete resolution of autoimmune disease (>90%)[3] [4]
- Most patients have complete resolution of lymphoproliferation, including lymphadenopathy and splenomegaly (>90%)
- Some patients have near complete response (disease flares with viral illness)
- A few patients have had partial responses (most commonly patient with non-cytopenia autoimmune disease)
- Most patients have elimination of peripheral blood DNTs
- mTOR/Akt/PI3K pathway may be activated in abnormal ALPS cells: mTOR inhibitors may be targeted therapy
- May not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune function with transition from cellcept to rapamycin[5]
- Not reported to cause hypogammaglobulinemia
- Hypothetically, may have lower risk of secondary cancers as opposed to other immune suppressants
- Always a risk with any agent in pre-cancerous syndrome as immune suppression can decreased tumor immunosurvellence
- mTOR inhibitors active against lymphomas, especially EBV+ lymphomas. Thus, THEORETICALLY could eliminate malignant clones.
- Requires therapeutic drug monitoring
- Goal serum trough 5-15ng/ml
- Drug-drug interactions
- Well tolerated: Side effects: mucositis, diarrhea, hyperlipidemia, delayed wound healing
- Consider PCP prophylaxis but usually not needed
- Other agents:
- Fansidar,[6] [7] mercaptopurine: More commonly used in Europe. Good ancedotal data
- Rituximab: AVOID. Can cause life long hypogammaglobulinemia[8]
- Splenectomy: AVOID. >30% risk of pneumococcal sepsis even with vaccination and antibiotic prophylaxis[9] [10]
- Mycophenolate mofetil (cellcept)[1]
References
- ↑ Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK; et al. (2005). "Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome". Br J Haematol. 129 (4): 534–8. doi:10.1111/j.1365-2141.2005.05496.x. PMID 15877736.
- ↑ Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J; et al. (2006). "Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)". Blood. 108 (6): 1965–71. doi:10.1182/blood-2006-01-010124. PMC 1895548. PMID 16757690.
- ↑ Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J; et al. (2009). "Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome". Br J Haematol. 145 (1): 101–6. doi:10.1111/j.1365-2141.2009.07595.x. PMC 2819393. PMID 19208097.
- ↑ Janić MD, Brasanac CD, Janković JS, Dokmanović BL, Krstovski RN, Kraguljac Kurtović JN (2009). "Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome". Pediatr Blood Cancer. 53 (6): 1117–9. doi:10.1002/pbc.22151. PMID 19588524.
- ↑ Teachey DT (2011). "Autoimmune lymphoproliferative syndrome: new approaches to diagnosis and management". Clin Adv Hematol Oncol. 9 (3): 233–5. PMID 21475130.
- ↑ van der Werff Ten Bosch J, Schotte P, Ferster A, Azzi N, Boehler T, Laurey G; et al. (2002). "Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations". Br J Haematol. 117 (1): 176–88. PMID 11918552.
- ↑ Rao VK, Dowdell KC, Dale JK, Dugan F, Pesnicak L, Bi LL; et al. (2007). "Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome". Am J Hematol. 82 (12): 1049–55. doi:10.1002/ajh.21007. PMID 17674358.
- ↑ Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J; et al. (2009). "Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)". Pediatr Blood Cancer. 52 (7): 847–52. doi:10.1002/pbc.21965. PMC 2774763. PMID 19214977.
- ↑ Rao VK, Oliveira JB (2011). "How I treat autoimmune lymphoproliferative syndrome". Blood. doi:10.1182/blood-2011-07-325217. PMID 21885601.
- ↑ Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L; et al. (2011). "A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation". Blood. doi:10.1182/blood-2011-04-347641. PMID 21885602.